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vención de manera oportuna aumentó en 11%. El costo por paciente sin EAG de
manera habitual fue de $16,981.77 mientras que con la intervención del farmacéu-
tico fue de $11,158.89. La razón costo efectividad incremental demostró que por
cada paciente adicional sin EAG el sistema de salud ahorra $40,405.18.
CONCLUSIONES: La inclusión del farmacéutico en el equipo de atención fue costo-
ahorradora.
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OBJECTIVES: The potential role of private health care providers and privatization
has been under heavy discussion in many countries. In the Hungarian health care,
there was a clearly supporting health policy regarding the increasing role of private
health care providers. The aim of the study is to analyze the market share of
for-profit private sector from the public health insurance expenditures on medical
services. METHODS: Data were derived from the nationwide administrative data-
set of the National Health Insurance Fund Administration (OEP), the only health
care financing agency in Hungary, covering the period 2006-2009. The analysis
includes the medical provisions (primary care, health visitors, dental care, out- and
inpatient care, home care, kidney dialysis, CT-MRI). We calculated the health in-
surance reimbursement according to the following categories of health care pro-
viders’ ownership status: local authorities, central government, for-profit compa-
nies and non-profit providers.RESULTS: In 2006 only 15.8% (112.8 billion Hungarian
Forint, HUF) of total expenditure for medical services went to for-profit private
providers, 53.9% to local authorities, 24.7% to central government and 5.6% to non-
profit sector. For 2009, the market share of private for-profit health care providers
increased to 30.9% (222.3 billion HUF), the local authorities had 43.8%, the central
government 22.7% and the non-profit sector 2.5% market share. We found the
largest increase of private for-profit health care providers in acute (from 0.8% in
2006 to 14.3 in 2009) and chronic care (from 1.1% in 2006 to 20.6% in 2009).
CONCLUSIONS: In line with the health policy objectives between 2006-2009, we
found a significant increase of private for-profit companies from health insurance
financing: they doubled their market share from 15.8% (2006) to 30.9% (2009). This
increase was attributed to the “functional” privatization of acute and chronic care
hospitals.
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OBJECTIVES: The aim of this review is to systematically summarize and assess the
existing economic evaluations of poison control centers (PCCs). METHODS: A lit-
erature search was performed to identify complete economic evaluations regard-
less of language or publication status by searching the following databases: Med-
line (via Pubmed), Embase, Centre for Reviews and Dissemination Databases,
Cochrane Library, Cochrane Central, metaRegister of Clinical Trials, LILACS, Sci-
ELO, ProQuest, Capes (Brazilian theses register) databases and abstracts at toxicol-
ogy congresses. Two reviewers assessed abstracts for inclusion and extracted the
data. Two experts assessed studies’ quality with a standardized tool (Drummond
2005). RESULTS:A total of 365 non-duplicated reports were identified, but only nine
met eligibility criteria. Five studies were published in the 1990s, and four were
published in the following decade. PCCs were compared to a scenario in which they
did not exist. Benefits were measured as potentially avoided healthcare charges.
Eight studies used cost-benefit analyses, and the other one used a cost-effective-
ness approach. Only two studies did not meet at least seven of 10 quality criteria.
Cost-benefit ratios ranged from 0.76 to 7.67, what means that each dollar spent on
poison centers saves almost US$ 8 in other medical spending. Incremental cost-
effectiveness ratios were US$ -12,000 for morbidity and -56,000 for mortality. These
results indicate that a significant cost savings is realized with each successful
outcome achieved by a poison center: US$ 12,000 in case of morbidity and US$
56,000 in case of mortality. CONCLUSIONS: Investment in PCCs appears to be a
rational public health policy. They could improve health care expenditure effi-
ciency and contribute to the sustainability of the health system. However, the
number of PCCs is decreasing in many countries.
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OBJECTIVES: To define the value medical services cost while conducting phar-
macoeconomic analysis. METHODS: A review of pharmacoeconomic researches of
5-alpha reductase inhibitors (5-ARI) application for treatment benign prostatic hy-
perplasia (BPH) has been conducted. The average prices for medical services for
care and treatment of BPH patients have been defined. The prices analysis of the
medical services Belarusian market in a urology specialty has been made. The
average prices comparison (in US dollars) of the actual medical services and prices
taken from medical literature has been done. RESULTS: The foreign medical liter-
ature review of using the 5-ARI for BPH patients shows the considerable economic
expenses because of an acute urinary retention hospitalization and surgical treat-
ment necessity. The medical services cost in Belarus is considerably cheaper to
compare with the costs given by foreign researchers’ reviews. We have specified
three procedures giving the significant contribution to the above-stated discrepan-
cies: the urologist examination cost in the USA 9 times exceeds the similar proce-
dure in our country (47,9$ versus 5$), transurethral resection (TURP) performance is
5 times (793$ versus 159$) and 1 day hospitalization cost without operative inter-
ventions and anesthesia is 364 times (4809$ versus 13,2$) more. CONCLUSIONS:
Hospital services and the medical staff work high cost in western countries allows
proving economically out-patient application of expensive treatment methods.
The end-points choice of the events demanding hospitalizations is not optimum at
making pharmacoeconomic researches in Belarus because of the low contribution
in hospital expenses versus the drug therapy cost. A complex approach with inte-
gration of several economic analyses is required to introduce new expensive inno-
vative drugs on the Belarusian pharmaceutical market.
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OBJECTIVES: After people living with HIV (PLWH) start on highly active antiretro-
viral therapy (HAART), rates of hospitalization for PLWH’s declined, but continued
still occurred at high levels. The increased prevalence of tobacco use among PLWH
and paucity of current data provide the rationale to study if tobacco use might
affect cost and clinical benefits of HAART among PLWH.METHODS:A decision-tree
model guided our assessment of the impact of tobacco on costs and effectiveness of
HAART by race/ethnicity. Using a payer perspective, the probabilities related with
smoke habit for racial group (African-Americans, Caribbeans, Hispanics, Cauca-
sians) were extracted from our prior tobacco study (n560) along with the number
of hospitalizations. This information along with hospital bed/day costs, provided
by Jackson Memorial Hospital’s patient accounting system, was used to estimate
the impact of the tobacco with a 1-year time frame. Results were express as cost per
hospitalizations related to smoking diseases (HRSD) RESULTS: Among patients
receiving antiretroviral therapy, our data indicated that smoking contributed a
$480,029 additional cost/year, with an average of $6,234/HRSD and an incremental
cost of $ 4,750 compared to non-smokers in the same treatment group. In the
Non-HAART Group, the incremental cost for smokers was $2,064,469, with an av-
erage of $8,054/HRSD and an incremental cost of $7,486. When racial group were
evaluated for smoking habit, the average costs for Hispanics receiving HAART was
$10,975/HRSD. African Americans despite the high cost reported for the total group
had an average cost of $8011/HRSD.CONCLUSIONS: In PLWH receiving HAART, our
analysis indicated that the benefits of HAART were negatively impacted by tobacco
use and costs are increased in the smokers in both the HAART and Non-HAART
groups. The data also indicated that focusing tobacco prevention efforts on minor-
ities may maximize effectiveness in terms of disease prevention and cost reduc-
tion.
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OBJECTIVOS:A un con un precio alto, la vacuna de VPH se ha asegura do una rápida
inclusión en los programas nacionales de inmunización (PNI) en economías avan-
zadas y emergentes. Por el contrario, otras vacunas nuevas, han encontrado una
aceptación más lenta en economías emergentes. El objetivo de esta investigación
es comparar el acceso al mercado de esta vacuna con los de las vacunas contra el
neumococo y la del Hib, con el fin de entender los criterios subyacentes en la
exitosa aceptación de una vacuna. METODOLOGÍAS: Cinco países de Latina
América fueron considerados en este estudio. Todos los países participaron en un
debate nacional de al menos dos de las vacunas sobre la inclusión en el PNI. Se
recopilaron los siguientes datos: fecha de autorización comercial y de inclusión en
el PNI, precio, restricciones de acceso y fuentes de financiación. Se llevó a cabo una
revisión cualitativa de la literatura y de las publicaciones de los Ministerios de
Salud de estos países para hacer un estudio comparativo de las tres vacunas.
RESULTADOS: Nuestro análisis muestra en todos los países una clara diferencia
entre la financiación del VPH y de las otras vacunas, con poca consistencia en el
razonamiento económico y político. Por ejemplo, los altos costos se citan como
barrera al acceso, sin embargo las poblaciones incluidas en los programas de va-
cunación del VPN son más grandes que en los países industrializados.
CONCLUSIONES: Los factores adicionales que influyen en la aceptación de una
vacuna varían dependiendo de los actores principales del debate nacional. Políti-
camente, las voces de los activistas contra el cáncer pueden aumentar la percep-
ción del valor social de una vacuna en particular. Estos factores son muy impor-
tantes y van más allá de la evaluación económica del proceso de inclusión de
vacunas en los PNIs.
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OBJETIVOS: O objetivo da investigação é comparar a qualidade de vida (QOL) de
pessoas portadoras de doenças crónicas com diagnóstico superior a três anos, com
pessoas da comunidade sem doença, do mesmo grupo etário e género. MÉTODOS:
Participam 603 indivíduos com 41,19 anos de idade média, escolaridade média de
9,87 anos, 72,5% mulheres, portadores de uma das seguintes doenças crónicas:
epilepsia, diabetes tipo 1 e 2, cancro, miastenia gravis, esclerose múltipla, obesi-
dade mórbida, com diagnóstico há mais de 3 anos. Depois de satisfazer as exigên-
cias éticas expressas nos códigos e na lei, avaliámos as seguintes variáveis: com-
ponentes, mental e físico, do MOS SF-36. O procedimento consistiu em subtrair o
valor de cada componente da população sem doença ao da população com doença.
RESULTADOS:No total, 28% da população com doença reportava qualidade de vida
superior à dos seus contrapartes sem doença. Estes valores variavam de modo
estatisticamente significativo entre doenças (20,002) com, respectivamente 10%
dos participantes com miastenia gravis reportando QOL superior, 35,8% no cancro,
23,4% na obesidade mórbida, 43% na epilepsia, 22% na esclerose múltipla, 20% na
diabetes tipo 2 e 32,5% na diabetes tipo 1. CONCLUSÕES: Os resultados mostram
que uma percentagem significativa de pessoas com doenças crónicas, controladas
e estabilizadas, vive com QOL superior à dos seus pares sem doença, embora esses
valores variem substancialmente com a doença. A idade não se correlaciona de
modo estatisticamente significativo com a diferença entre os grupos, para a com-
ponente mental e de modo estatisticamente significativo embora baixo (r0, 14)
para o componente físico: os grupos com idade mais jovem como a diabetes tipo 1 e
epilepsia mostram uma maior percentagem de pessoas com melhor QOL, mas os
com cancro exibem uma média de idade média mais elevada e a esclerose múltipla
idade mais baixa
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OBJECTIVES: Patient satisfaction is an important patient reported outcome (PRO)
that is being used to document the impact of pharmacists’ clinical services, espe-
cially in managing patients with chronic conditions. The purpose of this study was
to review literature on the validity and reliability of published instruments that
have been used to measure patient satisfaction with pharmaceutical care in the
community setting. METHODS: A structured search was conducted in five data-
bases (PUBMED, EMBASE, MEDLINE, PsycINFO, and OVID (1998–Feb. 2011) using
keywords to identify studies that measured patient satisfaction with pharmaceu-
tical care using survey instruments. Studies conducted outside United States,
those which used non-English language questionnaire; abstracts from confer-
ences, reviews, letters or notes were excluded. Studies reporting patient satisfac-
tion results and/or psychometric properties were included. RESULTS: A total of 21
studies were identified that met the selection criteria. The pharmacy practice set-
ting, sample size, study design in evaluating patient satisfaction varied greatly. The
survey instruments differed in number of items, response scale and mode of ad-
ministration. Majority of survey instrument were administered by mail. The re-
sponse rate varied from relatively low to very high. Patient satisfaction was a
secondary outcome in most of these studies. Majority of the studies used self
developed, non-validated or modified instrument with items from preexisting in-
struments. Only few studies reported psychometric properties of the instrument
used. Inconsistency in use of instrument measuring patient satisfaction was ob-
served. In general, studies reviewed showed greater degree of overall patient sat-
isfaction with the services. CONCLUSIONS: In majority of studies patient satisfac-
tion was measured using non-validated instruments. There is a lack of
comprehensive, valid and reliable instrument for assessing patient satisfaction
with pharmaceutical care services in community setting. Use of a standardized
survey instrument, sampling and study design will provide valuable insight into
patient evaluation of pharmacist services.
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OBJETIVOS: Esta investigação teve como objectivo identificar o nível de satisfação
dos profissionais e dos utentes de unidades de cuidados continuados, a sua dife-
rença, avaliar e identificar a influência de algumas variáveis. MÉTODOS: A metod-
ologia utilizada foi quantitativa, descritiva e exploratória. O questionário foi com-
posto por duas partes, questionário de Luís Graça e EORTC IN-PATSAT32,
respectivamente. RESULTADOS:A amostra foi constituída por 41 profissionais e 30
utentes. Os resultados encontrados mostraram a consistência de 7 das 18 hipóteses
formuladas. Os profissionais estavam mais satisfeitos com as dimensões “geral” e
“condições de trabalho”, apresentando menor nível de satisfação profissional com
a dimensão “salário”. Ao nível de satisfação dos utentes/clientes, estes estavam
mais satisfeitos com a dimensão “satisfação com os enfermeiros”, apresentando
menor nível de satisfação com a dimensão “satisfação com os médicos”.
CONCLUSÑES: Os dados confirmam a existência de correlação entre as dimensões
salário, tipo de vínculo, actividade profissional e estado civil com a satisfação
profissional relativamente aos profissionais de saúde, relativamente aos utentes/
clientes os dados confirmam a existência de correlação entre as dimensões “orga-
nização do serviço e cuidados”, “enfermeiros” e “serviço hospitalar de onde teve
alta” com a satisfação dos utentes/clientes, no que respeita ao serviço hospitalar de
onde teve alta, esta avaliação é algo de inovador. Salienta-se o facto de os utentes/
clientes e os profissionais de saúde se encontrarem na sua maioria satisfeitos, a
satisfação profissional, ao contrário da satisfação dos utentes/clientes, varia em
função da instituição. Será recomendável que as administrações monitorizem fre-
quentemente a satisfação, quer dos profissionais, quer dos utentes, no sentido de
ter um constante feedback, tendo conhecimento das dimensões em que há uma
maior satisfação ou insatisfação, tendo assim a possibilidade de apurar/estudar
alternativas para intervir no sentido de proporcionar uma maior satisfação, uma
vez que a satisfação é um dos principais pontos para o sucesso de uma organização.
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OBJECTIVES: In Mexico, two pilot studies in public hospitals assessed the economic
benefit of changing from a traditional, or ward stock, drug dispensing system to a
unit dose drug dispensing system. The aim of this study is to estimate the total drug
savings derived from implementing a unit dose system among hospitals at IMSS.
METHODS: Total and average hospital drug expenditures were estimated based on
hospital drug prescriptions data base for 2009. Statistical analysis was performed to
test for expenditure differences among levels of health care. The percentages of
economic savings derived from previous studies were used to construct three eco-
nomic benefit scenarios. These were applied to the total hospital drug expenditure.
The baseline scenario was obtained from studies in Mexico that reported economic
savings of 40%. A minimum and maximum scenario of 14.4% and 67.7% were
obtained from international studies. The exchange rate was of $12.10 pesos per
dollar. RESULTS: The total hospital drug expenditure was of USD $499.3 millions.
Most of the expenditure was derived from hospitals of general and specialized level
of care. Average expenditure and drug prescription dispensed were statistically
higher in the specialized compared to general hospitals (p0.0002 and p0.00009,
respectively). The total economic drug savings from the baseline scenario consid-
ering all hospitals was of USD$199.7 millions. In the maximum and minimum
scenarios, the economic savings were of USD$334.5 millions and USD$71.9 millions
respectively. On average savings were higher on specialized than in general
hospitals. CONCLUSIONS: The estimated economic benefits, derived from imple-
menting a unit drug dispensing system in hospitals at IMSS, was equivalent to 7.9%
of the 2009 institutional budget expenditure for medical related spending in the
baseline scenario. This suggests that this system can contribute to the contain-
ment of costs and the rational use of medicines on behalf of the patients and
institutions.
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OBJECTIVES: To assesses the extent of varying perspectives between health work-
ers and community members’ perception of decentralization and how such varia-
tion in views could affect the effective health services planning and management
in the Nanumba North District, Ghana. METHODS: A descriptive analytical cross
sectional survey with randomly selected community members aged 18 or more
years and health staff was undertaken from May – September 2009. Data collection
was done with the use of questionnaire and interview guide administered by uni-
versity trained research assistants to 186 respondents; 120 community members,
66 health staff who had stayed or worked in the district for the past 6-12months.
Data was analysed into descriptive statistics using the Statistical Package for Social
Sciences (SPSS) version 15.0. The significance or otherwise of the differences in
perspectives was ascertained using chi-square or fishers exact test with p-values of
0.05 or less and at 95% confidence interval. The study had ethical clearance and
Informed consent was sought from respondents. RESULTS: A majority of health
workers were females 74.2%, and young with average of 31.5yrs (SD, 9.3) and had
worked for 5yrs, 56.1%. Community members, 47.5%, were equally quite young
but slightly older, mean years 34.8, (SD 8.4), than health staff, and had lived in the
community for 5yrs. There was significant differences in perception between
health staff of whether or not the district management team (DHMT) was decen-
tralised, p0.05, and in perception regarding health planning process and manage-
ment of finances between health staff and community members, p0.05.
CONCLUSIONS: Differences in perception between health staff and community
members partly account for low community involvement in health planning and
management, health activities and utilisation of health service. A study involving
many DHMTs will be needed to make a case for policy change as the study focused
on only one district.
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OBJECTIVES: To assesses the predictors of appropriate use of insecticides treated
nets (ITNs) in the Asokwa Sub-Metropolitan Area of Kumasi, Ashanti, Ghana.
METHODS: The research was conducted in five communities in the Asokwa Sub-
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